Immune Design Corp. (IMDZ): Stephen R Brady , EVP, Strategy & Finance of Immune Design Corp. purchased 1,500 shares on Jul 15, 2016. The Insider buying transaction was reported by the company on Jul 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $6.84 per share for a total value of $10,255.35 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 24, 2015, Wayne Gombotz (Chief Development Officer) sold 5,000 shares at $20.00 per share price.On Aug 26, 2015, Lewis W Coleman (director) purchased 3,000 shares at $14.50 per share price.Also, On Apr 21, 2015, Franklin M Berger (director) purchased 25,000 shares at $26.50 per share price.
Immune Design Corp: On Monday, Jul 18, 2016 heightened volatility was witnessed in Immune Design Corp which led to swings in the share price. The shares opened for trading at $6.88 and hit $7.24 on the upside , eventually ending the session at $7.01, with a gain of 1.89% or 0.13 points. The heightened volatility saw the trading volume jump to 1,09,934 shares. The 52-week high of the share price is $27 and the company has a market cap of $141 M . The 52-week low of the share price is at $6.6401.
Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms ZVex and GLAAS which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action. The Company’s primary product candidates CMB305 and G100 utilize multiple immuno-oncology approaches and it believes address the shortcomings of existing therapies. The Company’s immuno-oncology product candidates are being developed in two separate approaches. The Specific Antigen approach uses selected antigens that are also present in the patient’s tumor. The Endogenous Antigen approach relies on endogenous tumor antigens released during tumor lysis by treatments such as chemotherapy or local radiation.